FY2024 Earnings Estimate for GLSI Issued By HC Wainwright

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Greenwich LifeSciences in a report released on Tuesday, February 11th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.80) per share for the year, up from their previous forecast of ($0.81). HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ FY2025 earnings at ($0.81) EPS.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ:GLSI opened at $12.30 on Friday. The firm has a 50 day moving average of $12.65 and a 200-day moving average of $13.53. Greenwich LifeSciences has a 12 month low of $8.70 and a 12 month high of $21.44.

Insider Activity

In other news, CEO Snehal Patel bought 3,200 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was bought at an average cost of $11.12 per share, for a total transaction of $35,584.00. Following the transaction, the chief executive officer now owns 5,539,302 shares of the company’s stock, valued at $61,597,038.24. This represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders bought 10,500 shares of company stock worth $128,459. 51.67% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of institutional investors have recently added to or reduced their stakes in GLSI. Garden State Investment Advisory Services LLC acquired a new position in Greenwich LifeSciences during the 3rd quarter worth approximately $253,000. Barclays PLC increased its position in Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after purchasing an additional 6,538 shares in the last quarter. Geode Capital Management LLC increased its position in Greenwich LifeSciences by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after purchasing an additional 5,861 shares in the last quarter. JPMorgan Chase & Co. increased its position in Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after purchasing an additional 4,465 shares in the last quarter. Finally, Brown Brothers Harriman & Co. acquired a new position in Greenwich LifeSciences during the 4th quarter worth approximately $45,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.